Latest Us Market News

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Mach7 Technologies has expanded its partnership with a major US radiology marketplace, signing a five-year licence amendment worth A$5 million that extends the contract by three years and adds significant value.

Adveritas Limited has raised $8.5 million through an oversubscribed institutional placement, positioning itself for expansion into the US market and accelerated product development.

Singular Health Group has inked a $1.3 million contract with Provider Network Solutions to deploy its 3DICOM imaging platform across key US states, backed by an $8 million capital raise to fuel national expansion.

Orthocell’s new study confirms Remplir™ delivers superior nerve regeneration and faster muscle recovery compared to traditional sutures, bolstering its US market rollout plans.

EZZ Life Science has launched its US-focused brand EZZDAY with four FDA-registered supplements, marking a major step in its international growth strategy. The company has also begun US-based manufacturing and opened an online store to target American consumers.

KMD Brands reports mixed sales across its portfolio with a notable rebound in Kathmandu’s direct-to-consumer sales and robust online growth, while managing tariff uncertainties and margin pressures.

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.

Ionic Rare Earths is broadening its Viridion Joint Venture to include a US-based rare earth refinery, aiming to strengthen a secure supply chain for critical magnet and heavy rare earth oxides outside China.

Australian Strategic Materials (ASM) has announced an underwritten share purchase plan to raise up to A$3 million, supporting its advancing Dubbo Project and ramp-up of the Korean Metals Plant. The company also outlines ambitions for a US metals facility amid strong government backing and strategic partnerships.

Artrya Limited has submitted a pivotal FDA 510(k) application for its AI-powered Salix® Coronary Plaque module, aiming for clearance in Q3 2025 and a lucrative US commercial launch.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.